368 related articles for article (PubMed ID: 23787155)
1. Effect of anemia correction on left ventricular hypertrophy in patients with modestly high hemoglobin level and chronic kidney disease .
Akaishi M; Hiroe M; Hada Y; Suzuki M; Tsubakihara Y; Akizawa T;
J Cardiol; 2013 Oct; 62(4):249-56. PubMed ID: 23787155
[TBL] [Abstract][Full Text] [Related]
2. Target level for hemoglobin correction in patients with diabetes and CKD: primary results of the Anemia Correction in Diabetes (ACORD) Study.
Ritz E; Laville M; Bilous RW; O'Donoghue D; Scherhag A; Burger U; de Alvaro F;
Am J Kidney Dis; 2007 Feb; 49(2):194-207. PubMed ID: 17261422
[TBL] [Abstract][Full Text] [Related]
3. [Improvement of left ventricular hypertrophy by anemic-correcting erythropoietin therapy in chronic renal insufficiency].
Jiang JP; Hou FF; Gao LZ; Pan YB; Yang NS; Chen W; Shu GY; Chen YM; Chen J; Peng WH; Wu JP; Yang ZM
Zhonghua Nei Ke Za Zhi; 2005 Jan; 44(1):25-9. PubMed ID: 15769393
[TBL] [Abstract][Full Text] [Related]
4. Darbepoetin alfa once monthly corrects anaemia in patients with chronic kidney disease not on dialysis.
Roger SD; Kolmakova E; Fung M; Malecki R; Vinhas J; Dellanna F; Thomas M; Manamley N; Ferenczi S
Nephrology (Carlton); 2014 May; 19(5):266-74. PubMed ID: 24506498
[TBL] [Abstract][Full Text] [Related]
5. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
[TBL] [Abstract][Full Text] [Related]
6. Hemoglobin stability in patients with anemia, CKD, and type 2 diabetes: an analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) placebo arm.
Skali H; Lin J; Pfeffer MA; Chen CY; Cooper ME; McMurray JJ; Nissenson AR; Remuzzi G; Rossert J; Parfrey PS; Scott-Douglas NW; Singh AK; Toto R; Uno H; Ivanovich P
Am J Kidney Dis; 2013 Feb; 61(2):238-46. PubMed ID: 23159232
[TBL] [Abstract][Full Text] [Related]
7. Rationale and study design of a randomized controlled trial to assess the effects of maintaining hemoglobin levels using darbepoetin alfa on prevention of development of end-stage kidney disease in non-diabetic CKD patients (PREDICT Trial).
Imai E; Maruyama S; Nangaku M; Hirakata H; Hayashi T; Narita I; Kono H; Nakatani E; Morita S; Tsubakihara Y; Akizawa T
Clin Exp Nephrol; 2016 Feb; 20(1):71-6. PubMed ID: 26081567
[TBL] [Abstract][Full Text] [Related]
8. Epoetin alfa and darbepoetin alfa: effects on ventricular hypertrophy in patients with chronic kidney disease.
Chen HH; Tarng DC; Lee KF; Wu CY; Chen YC
J Nephrol; 2008; 21(4):543-9. PubMed ID: 18651544
[TBL] [Abstract][Full Text] [Related]
9. Positive outcomes of high hemoglobin target in patients with chronic kidney disease not on dialysis: a randomized controlled study.
Akizawa T; Gejyo F; Nishi S; Iino Y; Watanabe Y; Suzuki M; Saito A; Akiba T; Hirakata H; Fukuhara S; Morita S; Hiroe M; Hada Y; Suzuki M; Akaishi M; Iwasaki M; Tsubakihara Y;
Ther Apher Dial; 2011 Oct; 15(5):431-40. PubMed ID: 21974695
[TBL] [Abstract][Full Text] [Related]
10. Effects of anemia correction by erythropoiesis-stimulating agents on cardiovascular function in non-dialysis patients with chronic kidney disease.
Suzuki M; Hada Y; Akaishi M; Hiroe M; Aonuma K; Tsubakihara Y; Akizawa T
Int Heart J; 2012; 53(4):238-43. PubMed ID: 22878802
[TBL] [Abstract][Full Text] [Related]
11. Italian randomized trial of hemoglobin maintenance to prevent or delay left ventricular hypertrophy in chronic kidney disease.
Cianciaruso B; Ravani P; Barrett BJ; Levin A;
J Nephrol; 2008; 21(6):861-70. PubMed ID: 19034870
[TBL] [Abstract][Full Text] [Related]
12. The cardiovascular and hemodynamic effects of erythropoietin in chronic renal failure.
Singh NP; Chandrashekhar ; Nair M; Anuradha S; Kohli R; Agarwal SK
J Assoc Physicians India; 2000 Mar; 48(3):301-6. PubMed ID: 11229114
[TBL] [Abstract][Full Text] [Related]
13. Normalization of hemoglobin level in patients with chronic kidney disease and anemia.
Drüeke TB; Locatelli F; Clyne N; Eckardt KU; Macdougall IC; Tsakiris D; Burger HU; Scherhag A;
N Engl J Med; 2006 Nov; 355(20):2071-84. PubMed ID: 17108342
[TBL] [Abstract][Full Text] [Related]
14. [Multicenter study of darbepoetin alfa in the treatment of anemia secondary to chronic renal insufficiency on dialysis].
Martínez Castelao A; Reyes A; Valdés F; Otero A; López de Novales E; Pallardó L; Tabernero JM; Hernández Jaras J; Lladós F
Nefrologia; 2003; 23(2):114-24. PubMed ID: 12778875
[TBL] [Abstract][Full Text] [Related]
15. Canadian randomized trial of hemoglobin maintenance to prevent or delay left ventricular mass growth in patients with CKD.
Levin A; Djurdjev O; Thompson C; Barrett B; Ethier J; Carlisle E; Barre P; Magner P; Muirhead N; Tobe S; Tam P; Wadgymar JA; Kappel J; Holland D; Pichette V; Shoker A; Soltys G; Verrelli M; Singer J
Am J Kidney Dis; 2005 Nov; 46(5):799-811. PubMed ID: 16253719
[TBL] [Abstract][Full Text] [Related]
16. Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia.
van Veldhuisen DJ; Dickstein K; Cohen-Solal A; Lok DJ; Wasserman SM; Baker N; Rosser D; Cleland JG; Ponikowski P
Eur Heart J; 2007 Sep; 28(18):2208-16. PubMed ID: 17681958
[TBL] [Abstract][Full Text] [Related]
17. Impact of hemoglobin concentration on plasma B-type natriuretic peptide level and left ventricle echocardiographics characteristics in chronic kidney disease patients.
Rasić S; Hadzović-Dzuvo A; Tomić M; Uncanin S; Corić S
Coll Antropol; 2009 Dec; 33 Suppl 2():141-4. PubMed ID: 20120531
[TBL] [Abstract][Full Text] [Related]
18. Cardiac mortality prevention in uremic patients. Therapeutic strategies with particular attention to complete correction of renal anemia.
Berweck S; Hennig L; Sternberg C; Dingerkus H; Ludat K; Hampl H
Clin Nephrol; 2000 Feb; 53(1 Suppl):S80-5. PubMed ID: 10746811
[TBL] [Abstract][Full Text] [Related]
19. Darbepoetin alfa administered every other week maintains hemoglobin levels over 52 weeks in patients with chronic kidney disease converting from once-weekly recombinant human erythropoietin: results from simplify the treatment of anemia with Aranesp (STAAR).
Hertel J; Locay H; Scarlata D; Jackson L; Prathikanti R; Audhya P
Am J Nephrol; 2006; 26(2):149-56. PubMed ID: 16636531
[TBL] [Abstract][Full Text] [Related]
20. Erythropoietin improves anemia exercise tolerance and renal function and reduces B-type natriuretic peptide and hospitalization in patients with heart failure and anemia.
Palazzuoli A; Silverberg D; Iovine F; Capobianco S; Giannotti G; Calabrò A; Campagna SM; Nuti R
Am Heart J; 2006 Dec; 152(6):1096.e9-15. PubMed ID: 17161060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
